Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
This is the fourth injection site
There is no promotional first-month introductory rate that spikes at the first refill a pricing structure that has generated significant patient confusion at several competing platforms in the current market
GLP-1 weight loss injections restore these signals, making sustained weight loss achievable
However, brand trust, IP defense, and clinical validation will remain Novo and Lillys strongest moats in premium markets such as the USA, EU, and Japan, where regulatory standards and reimbursement frameworks still favor established innovators
The company said a "strategic shift" means it will now focus on "an increasing variety of FDA-approved GLP-1s," making compounded semaglutide available only to patients whose physician determines that it is "clinically necessary." Under US regulations, compounders can only provide in-patent medicines that are in short supply which no longer applies to semaglutide or in niche applications to provide personalised formulations not available from the original manufacturer
